RNA-seq profiles between human parental and 5-FU drug resistant HCT116 and SW480 colorectal cancer cell lines

Colorectal cancer (CRC) is one of the most frequently diagnosed and lethal malignancy. Several key factors including poor dietary habits, smoking, alcohol consumption, genetic predisposition, obesity, diabetes mellitus, and sedentary lifestyle – all result in a significantly increased risk for developing CRC. Current treatment modalities for patients with CRC include surgery, which is often followed with adjuvant chemotherapy, especially in patients with a stage II and III disease. Most patients with advanced CRC are generally treated with the chemotherapeutic drug, 5-fluorouracil (5-FU) – either given alone or in combination with oxaliplatin and other molecularly-targeted drugs. While such treatment regimens are effective at improving disease outcomes, their clinical usefulness is often hampered due to the considerable toxicity associated with these treatments, which often causes severe nausea, vomiting, weight loss, and risk of infectious complications due to immunosuppression. Furthermore, their therapeutic efficacy is limited due to the emergence of chemotherapeutic drug resistance. In this study we performed genomewide transcriptomic analysis of parental and 5-FU resistant cells to identify differentially expressed genes and its associated pathways in promoting chemoresistance in CRC. Overall design: RNA-seq profiles between human parental and 5-FU drug resistant HCT116 and SW480 colorectal cancer cell lines.

结直肠癌（Colorectal Cancer, CRC）是全球最常见且致死性最强的恶性肿瘤之一。多项关键危险因素包括不良饮食习惯、吸烟、饮酒、遗传易感性、肥胖、糖尿病及久坐不动的生活方式，均可显著升高CRC的发病风险。当前CRC患者的治疗手段以手术为主，术后通常辅以辅助化疗，尤其针对II、III期疾病患者。多数晚期CRC患者一般采用化疗药物5-氟尿嘧啶（5-FU）单药治疗，或联合奥沙利铂及其他分子靶向药物。尽管此类治疗方案可有效改善疾病预后，但其临床应用常因治疗相关的显著毒性反应而受到限制——这类毒性可引发严重恶心、呕吐、体重下降，以及免疫抑制导致的感染并发症风险。此外，化疗耐药的出现也限制了其治疗效果。本研究对亲本细胞与5-FU耐药细胞开展全基因组转录组分析，以鉴定CRC化疗耐药相关的差异表达基因及其调控通路。实验设计：检测人类亲本及5-FU耐药的HCT116与SW480结直肠癌细胞系的RNA测序（RNA-seq）表达谱。